Major advances in the management of paraneoplastic neurologic disorders (PND) include the detection of new antineuronal antibodies, the improved characterisation of known syndromes, the discovery of new syndromes, and the use of CT and PET to reveal the associated tumours at an early stage. In addition, the definition of useful clinical criteria has facilitated the early recognition and treatment of these disorders. In this article, we review some classic concepts about PND and recent clinical and immunological developments, focusing on paraneoplastic cerebellar degeneration, opsoclonus-myoclonus, and encephalitides affecting the limbic system.
Introduction
In 1949, Guichard and Vignon 1 used the term paraneoplastic in a discussion of the differential diagnosis of a patient with multiple cranial and radicular neuropathies caused by metastases of a neoplasm of the uterus. Guichard and colleagues 2 subsequently studied three patients suspected of having similar metastatic neuropathies, the autopsies of whom did not reveal neoplastic cells in their spinal cords and nerve roots. These authors proposed that the term paraneoplastic was more appropriate than neoplastic to describe such polyneuropathies. The same term was later used to describe many complications that could not be attributed to identifiable mechanisms, such as direct invasion of the nervous system by the neoplasm, infections, coagulopathy, or side-effects of cancer treatment. Therefore, any symptom of unclear cause but associated with the presence of a neoplasm was considered paraneoplastic. Over the past 20 years, the discovery that many paraneoplastic neurological disorders (PND) are associated with antineuronal antibodies has resulted in tests that, along with recently defined clinical criteria, facilitate their diagnosis. Consequently, patients are diagnosed faster and treated earlier and more effectively than in the past. Patients whose symptoms do not conform to any of the classic PND or who do not have antineuronal antibodies have been studied further, resulting in the discovery of disorders that, in fact, are immune mediated and associated with new antibodies that are likely to be pathogenic.
In this Review, we focus on recent developments and new concepts in PND related to paraneoplastic cerebellar degeneration, opsoclonus-myoclonus, and encephalitides (table 1) . 3-5 Comprehensive reviews of PND of the peripheral nervous system have recently been reported in The Lancet Neurology and elsewhere; 3-6 we do not address these disorders or those affecting the spinal cord and visual system in this Review.
Epidemiology
Some researchers suggest that about one per 10 000 patients with cancer develop PND, 7 although there are no data to support such a low prevalence. A report based on serological screening of patients with suspected PND without further selection criteria showed that among 60 000 consecutive cases examined in 4 years, 553 (0·9%) were positive for antibodies associated with PND. 8 By contrast, a review of patients examined in a research laboratory in which most samples are preselected by use of clinical criteria showed that among 649 cases consecutively examined in 23 months, 163 (25%) were serologically positive (Dalmau J, unpublished) . Neither of these numbers shows the true prevalence of PND, but they do emphasise the importance of clinical criteria.
Tumours commonly involved in PND of the CNS express neuroendocrine proteins (eg, smallcell lung cancer, neuroblastoma), affect organs with immunoregulatory properties (thymoma), or contain mature or immature neuronal tissue (teratomas). Tumours that derive from cells that produce immunoglobulins (plasma-cell dyscrasias, B-cell lymphomas) are more commonly involved in PND of the peripheral nervous system than other tumour types. 9 About 3-5% of patients with small-cell lung cancer, 10 15-20% with thymomas, and 3-10% with B-cell or plasma-cell neoplasms develop PND. The prevalence of PND in other neoplasms, including cancer of the breast or ovary and others cancers, is well below 1%.
Immune responses and pathogenic mechanisms
Most PND of the CNS are probably immune mediated, the best evidence for which comes from the demonstration of antineuronal antibodies in the CSF and serum of patients (table 2) . These antibodies react with neuronal proteins that are usually expressed by the patients' tumour, and their detection is the basis of useful diagnostic tests.
Antibody-mediated PND
Some antibodies seem to have a direct pathogenic role in causing PND. These antibodies usually react with cell-surface antigens and until recently were thought to be mainly involved in syndromes of the neuromuscular junction or peripheral nerves. The associated symptoms and electrophysiological abnormalities of most of these immune responses have been modelled in animals. Antibodies to cell-surface antigens and the associated disorders can occur with or without cancer. 11 The relative risk of a paraneoplastic cause depends on the type of syndrome; for example, the likelihood of an underlying tumour is higher in the Lambert-Eaton myasthenic syndrome (50%, commonly small-cell lung cancer) than in myasthenia gravis (10%, typically thymoma). 12 Some patients with paraneoplastic cerebellar degeneration have antibodies against P/Q type voltage-gated calcium channels. 13 Similarly, antibodies against voltage-gated potassium channels are associated not only with peripheral nerve hyperexcitability, but also with limbic encephalitis and Morvan's syndrome. 14,15
Antibodies against mGluR1 were identified in two patients who developed cerebellar ataxia after being in remission from Hodgkin's lymphoma for 2 years and 9 years. Passive transfer of these antibodies to the cerebellar subarachnoid space of mice caused severe, reversible ataxia. 16 No other patients have been reported, suggesting that this disorder is uncommon. However, the description of antibodies to Homer 3, an mGluR1 C-terminus-interacting protein, in a patient with idiopathic cerebellar ataxia suggests that autoimmunity to synaptic metabotropic proteins results in cerebellar dysfunction . 17 Antibodies to N-methyl-D-aspartate (NMDA) receptors seem to be associated with a severe form of encephalitis that usually presents with psychiatric symptoms and less commonly with short-term memory deficits. 18 These antibodies react with cell-surface epitopes that are present in NR1/NR2 heteromers of NMDA receptors and might be pathogenic.
Other disorders for which a humoral immuno-pathogenesis is strongly suggested include the cerebellar and stiff-person syndromes associated with antibodies against glutamic acid decarboxylase, and the paraneoplastic stiff-person syndrome related to antibodies against amphiphysin. Glutamic acid decarboxylase and amphiphysin are intracellular, close to the synaptic membrane, and antibodies against them seem to have a functional effect in vivo. 19, 20 In the rat model that involved systemic passive transfer of patients' IgG-containing amphiphysin antibodies, the functional effects were observed after disruption of the bloodbrain barrier with encephalitogenic T-helper lymphocytes specific for myelin basic protein. 20
T-cell-mediated PND
In contrast to the above disorders, other PND of the CNS seem to be mediated by T-cell immune responses that are probably directed against the target antigens of the accompanying antibodies. The best, but still circumstantial, evidence of T-cell-mediated pathogenesis comes from studies of patients with anti-Yo (also known as cdr2) or anti-Hu antibodies in whom cdr2-specific or Hu-specific T cells have been identified in the blood or CSF. 21-23 However, some of the initial findings related to cdr2-specific T-cells in patients' blood have not been reproduced by other investigators using interferon-γ ELISPOT and highly sensitive immune-assessment assays. 24,25 One study suggested that anti-Hu antibodies induced apoptosis when applied to cultures of neuroblastoma or myenteric cells. 26 However, all attempts to model the PND associated with these immune responses by passive transfer of antibodies or by protein or DNA immunisation failed to reproduce the symptoms. 27-29 Adoptive transfer of T cells specific for autologous Ma1 in rats produced perivascular and meningeal lymphocytic infiltrates that were indistinguishable from those induced by CD4+ T cells against myelin proteins. 30 However, the rats did not develop symptoms or pathological features that characterise PND, such as predominant parenchymal inflammatory infiltrates in the hippocampi, brainstem, or diencephalon, neuronophagic nodules of T-cells, neuronal degeneration, and gliosis. 31
Further support for T-cell-mediated mechanisms in some PND of the CNS comes from the following findings: difficulty in treating these disorders with strategies directed at the humoral immune response; 32-34 the presence of extensive infiltrates of T cells in the CNS of patients; 35,36 and the presence of oligoclonal cytotoxic T-cell infiltrates in the brains and tumours of patients with anti-Hu-associated encephalomyelitis, suggesting a specific antigen-driven clonal expansion of T cells. 37
Diagnosis of PND
The initial diagnostic approach in patients with suspected PND of the CNS (figure 1) is straightforward for patients with a classic syndrome in association with well characterised paraneoplastic antibodies or a demonstrable tumour (tables 1 and 2). However, not all patients have well characterised paraneoplastic antibodies, and other clinical scenarios are common, including patients with atypical syndromes or those whose tumour cannot be found. In such cases, a firm diagnosis of PND is difficult to establish even when a brain biopsy is done, as other disorders can have similar pathological signs. To resolve some of these issues, specific diagnostic criteria have been defined (panel). 38 Recent developments suggest that an expansion of these criteria is already needed.
Two clinical features shared by most PND of the CNS are the rapid development of symptoms and signs of inflammation in the CSF, including moderate lymphocytic pleocytosis, increased protein concentration, high IgG index, and CSF-specific oligoclonal bands. In about 70% of patients with PND, neurological symptoms are the first manifestation of a tumour. 39 Of these patients, 70-80% will have a positive screening for cancer on initial assessment. Most tumours are identified with imaging of the chest, abdomen, and pelvis using CT, fluorodeoxyglucose-PET, or both. 40,41 Some tumours of the gonads might require a different approach. For example, mature ovarian teratomas do not have uptake of fluorodeoxyglucose and are better shown with CT, MRI, or pelvic and transvaginal ultrasound. Microscopic intratubular germcell testicular neoplasms are not visible with any tests. 42 However, the associated PND, age of the patients (usually younger than 50 years), and common development of testicular microcalcifications lead to further studies, such as repeat ultrasound, biopsy, or unilateral orchiectomy, that eventually reveal the tumour. 
Panel

Paraneoplastic cerebellar degeneration
Cerebellar dysfunction is one of the most common paraneoplastic presentations of cancer. The tumours more commonly involved are small-cell lung cancer, gynaecological and breast tumours, and Hodgkin's lymphoma. 34,43,44 Neurological deficits are sometimes preceded by prodromal symptoms, such as a viral-like illness, dizziness, nausea, or vomiting that might be attributed to a peripheral vestibular process. 45 These symptoms are followed by gait unsteadiness that rapidly develops into ataxia, diplopia, dysarthria, and dysphagia. Some patients have blurry vision, oscillopsia, and transient opsoclonus. 44, 46, 47 Initial MRI is normal in most patients, although some have transient diffuse cerebellar hemispheric enlargement or cortical-meningeal enhancement (figure 2). 48 During this early stage of the syndrome, fluorodeoxyglucose-PET can show cerebellar hyper-metabolism. 49 Over time, MRI shows cerebellar atrophy and PET demonstrates hypometabolism.
Common considerations in the differential diagnosis (table 3) are viral cerebellitis, CreutzfeldtJakob disease, and glutamic-acid-decarboxylase-associated cerebellar degeneration. Creutzfeldt-Jakob disease can mimic paraneoplastic cerebellar degeneration at onset; furthermore, 12·5% of patients with paraneoplastic syndromes of the CNS have 14-3-3 protein in the CSF, so this protein cannot distinguish the two disorders. 50 Compared with paraneoplastic cerebellar degeneration, the syndrome associated with antibodies against glutamic acid decarboxylase has a slower progression, results in a milder and asymmetric limb ataxia (mainly affecting gait), is associated with polyendocrine dysfunction (late-onset insulindependant diabetes mellitus, thyroiditis, pernicious anaemia), 51 and might present with transient or self-limited muscle spasms without developing into stiff-person syndrome. 52
The hallmark of paraneoplastic cerebellar degeneration is an extensive loss of Purkinje cells that might be associated with inflammatory infiltrates in the cerebellar cortex, deep cerebellar nuclei, and inferior olivary nuclei (figure 3). Patients with predominant cerebellar ataxia rarely die as a result of the neurological disorder; thus, neuropathological studies are uncommon and only those obtained at the early stage of the disease show inflammatory infiltrates. 53,54
An increasing number of immune responses are associated with paraneoplastic cerebellar degeneration (table 2) . Some are specifically related to cerebellar symptoms, whereas others have no syndrome specificity and might simply reflect a tumour-induced immune response. Anti-Yo (cdr2), usually related to the presence of a gynaecological or breast cancer, 44,55 and anti-Tr, often associated with Hodgkin's lymphoma, 56 are immune responses with high syndrome specificity.
Patients with small-cell lung cancer can develop one or multiple immune responses in association with paraneoplastic cerebellar degeneration. 43 In this setting, up to 41% of patients develop antibodies against voltage-gated calcium channels with or without associated Lambert-Eaton myasthenic syndrome, 23% develop anti-Hu antibodies, and a minority develops other antibodies, such as antibodies against collapsin-response mediator protein 5 (CRMP or CV2), amphiphysin, Purkinje cell cytoplasmic antibody type 2 (PCA2), and antineuronal nuclear antibody 3 (ANNA3). 13,47,57,58 In contrast to the antibodies that target intracellular antigens, antibodies against voltage-gated calcium channels react with cell-surface epitopes; this and the fact that some patients have intrathecal synthesis of such antibodies has suggested a direct pathogenic role in the cerebellar dysfunction.
Recently described immune responses associated with cerebellar degeneration (table 4) 59-69 have been found in only a few patients or in association with well characterised antibodies, but their clinical significance is unclear.
There is no standard of care for any of these syndromes. Clinical experience suggests that treatment of the tumour is needed for stabilisation or symptom improvement with or without immunotherapy. The use of corticosteroids, plasma exchange, intravenous immunoglobulin, cyclophosphamide, and tacrolimus did not substantially modify the neurological outcome of patients whose tumours were successfully treated. 32,70,71 However, there are case reports of an apparent benefit from immunotherapy. 72,73 The immune responses associated with more severe neurological deficits (Yo, Hu, CRMP5) are also the most refractory to treatment. Survival from time of diagnosis is significantly worse in patients with anti-Yo (median 13 months) or anti-Hu (median 7 months) than in patients with anti-Tr (median >113 months) or anti-Ri (median >69 months). 34 Patients who received antitumour treatment, with or without immunotherapy, lived significantly longer than those who did not. 34
The largest group of patients with paraneoplastic cerebellar degeneration without identifiable immune responses comprises those with non-small-cell lung cancer. In a study of nine patients, two had full neurological recovery and one had partial recovery after treatment of the tumour. 61 In children with paraneoplastic opsoclonus, the immunotherapies used include corticosteroids, adrenocorticotropic hormone, intravenous immunoglobulin, plasma exchange, cyclophosphamide, or rituximab. 84 Although opsoclonus commonly responds to treatment, the high frequency of residual motor, speech, behavioural, and sleep disorders is an important problem. 85 Trazodone improves the sleep and behavioural problems of some patients. 86 Symptom relapses can occur during intercurrent illnesses (eg, viral infections).
Opsoclonus-myoclonus
In adults, paraneoplastic opsoclonus-myoclonus is less responsive to immunotherapy. Corticosteroids or intravenous immunoglobulin might speed up improvement in patients with idiopathic opsoclonus, but not in those with paraneoplastic opsoclonus; the latter only responded when the tumour was controlled. 87 Immunotherapy seems to be helpful, but improvement is mild or not sustained unless the tumour is controlled. 88
Limbic encephalitis and variants
Limbic encephalitis is an inflammatory process highly confined to structures of the limbic system. Patients develop mood and sleep disturbances, seizures, hallucinations, and short-term memory loss that can progress to dementia. 89 Electroencephalography usually reveals foci of epileptic activity in one or both temporal lobes or focal or generalised slow activity. 
Limbic encephalitis with antibodies to intracellular antigens
The main intracellular antigens related to limbic encephalitis are Hu, Ma2, and less frequently CRMP5 and amphiphysin. In these immune responses, cytotoxic T-cell mechanisms are the main pathogenic effectors. 
Anti-Hu-Many
Encephalitis with antibodies to neuronal cell-surface antigens
Antibodies against voltage-gated potassium channels-The two main CNS syndromes associated with these antibodies are typical limbic encephalitis and a less focal encephalitis that is associated with psychiatric symptoms, hallucinations, peripheral nerve hyperexcitability, hyper-hydrosis, and other symptoms of autonomic dysfunction (Morvan's syndrome). 14,96 REM sleep disturbances and hyponatraemia are common in both, 120 and some patients develop hypothermia, hypersalivation, pain, and disorders of appetite. 121 Symptoms of limbic encephalitis might be preferentially related to antibodies against the Kv1.1 subunit of the potassium channel whereas symptoms of neuromyotonia and Morvan's syndrome might be more closely related to antibodies to Kv1.2; standard clinical tests with immunoprecipitation assays do not differentiate between these subunits. 122
About 30% of patients with antibodies against voltage-gated potassium channels have tumours; but only 20% have tumours if small-cell lung cancers and thymomas are considered alone. 97 The neurological prognosis seems worse in patients with lung cancer and limbic encephalitis associated with these antibodies than in those without lung cancer. 123
Compared with other paraneoplastic or immune-mediated limbic encephalitis, the CSF of patients with antibodies against voltage-gated potassium channels shows less pleocytosis and lower protein concentration and intrathecal synthesis of IgG. 92,124 Treatment comprises corticosteroids, plasma exchange, or intravenous immunoglobulin. About 80% of patients respond to these treatments. 6% of patients with long-standing epilepsy, 125 one patient with hyper-ekplexia, 126 and some people without neurological symptoms (Dalmau J, unpublished) have antibodies against these channels.
Antibodies against NMDA receptors-Most patients with this disorder are young women who, after prodromal symptoms that can include headache, fever, or a viral-like illness, develop severe psychiatric symptoms or memory loss, seizures, and decreased consciousness accompanied by dyskinesias, 127 hypo-ventilation, or autonomic instability. 18 Symptoms commonly develop in sequence so that most patients are initially seen in or admitted to psychiatric centres and eventually transferred to intensive-care units. While unresponsive, patients are described to be in a catatonic-like stage, with limited eye contact or visual tracking, and paradoxical responses (eg, resisting eye opening while unresponsive to pain-inducing stimuli). 128,129 Autonomic instability includes fluctuations of blood pressure, cardiac rhythm (from tachycardia to bradycardia or cardiac pauses), hyperthermia, and sialorrhea.
About 65% of patients have an underlying tumour, usually a cystic ovarian teratoma. The teratoma can be mature or immature, difficult to demonstrate, or, if found, difficult to remove because of the unstable clinical condition. Immunotherapy (corticosteroids, plasma exchange, intravenous immunoglobulin, rituximab, or cyclophosphamide) often results in improvement thereby enabling tumour removal. 130 Patients who do not respond to one form of immunotherapy might respond to another. Improvement can be slow and take several months. When a tumour is found, removal expedites recovery and decreases relapses. In a review of 69 patients, 65% had full or near-full recovery, and many returned to work. The disorder has recently been identified in children and a few men without tumour. 131
Some patients previously described as having acute diffuse lymphocytic meningoencephalitis, juvenile acute non-herpetic encephalitis, or acute juvenile female non-herpetic encephalitis had anti-NMDA receptor encephalitis. 129 Owing to the profile of symptoms and orofacial dyskinesias, a few patients were initially suspected to have rabies.
Other immune responses to cell-membrane antigens-There are other antibodies to cell-surface antigens that have not been fully characterised (figure 5). Some of these antibodies occur along other well characterised immune responses, such as glutamic acid decarboxylase antibodies, and the associated disorders (eg, limbic encephalitis, muscle rigidity, and spasms) respond differently to immunotherapy. 92 Whether these new antibodies have one or several target antigens is unclear. Tumours found in association with these antibodies include thymoma, small-cell lung cancer, and Hodgkin's lymphoma; similar antibodies might occur with non-paraneoplastic limbic encephalitis. 98
Antibodies against the subunit ε2 (or GluRε2, also known as NR2B) of the NMDA receptor (not to be confused with antibodies against NR1/NR2 heteromers) have been reported in an extensive number of non-paraneoplastic syndromes, including Rasmussen's encephalitis, chronic epilepsy, limbic encephalitis, and stroke. 132,133 These antibodies are detectable with immunoblotting of GluRε2 (which differentiates them from antibodies against NR1/NR2) and have poor syndrome specificity. One patient with encephalitis and ovarian teratoma had GluRε2 antibodies; 69 NR1/NR2 antibodies were not determined.
Additional considerations and future research
Progress in the study of PND is so rapid that recently defined clinical criteria already need expansion. For example, the discovery that SOX, a protein related to small-cell lung cancer, is the target of antibodies in 65% of patients with cancer-associated Lambert-Eaton myasthenic syndrome provides a potential test for differentiating paraneoplastic from non-paraneoplastic Lambert-Eaton myasthenic syndrome. 134 Anti-SOX antibodies seem to have the same predictive value of a paraneoplastic cause when detected in patients with limbic encephalitis and antibodies against voltage-gated potassium channels. 135 In addition, newly discovered disorders, such as the encephalitis associated with antibodies to NR1/NR2 heteromers of NMDA receptors, have been identified. Because the associated syndrome is highly predictable, it can now be added to the list of typical syndromes in the indicated criteria. 38
Treatment of PND of the CNS is challenging, particularly for disorders associated with antibodies to intracellular antigens that probably cause neuronal damage by cytotoxic-T-cell mechanisms. A review of several series of patients with these disorders emphasises the disappointing results of immuno therapy. 34,93,99,100 However, these large series were gathered over many years, when the diagnoses of PND and associated tumours were delayed, unlike the early diagnoses that can now be made. Recent studies, and our experience, suggest that the combination of intravenous immunoglobulin or plasma exchange with cyclo phosphamide might be effective in some cases. 136 The role of rituximab for these disorders is uncertain; in one study three of nine patients with anti-Hu or anti-Yo antibodies had some improvement, and a clinical trial is warranted. 137 The use of tacrolimus might downregulate cdr2-specific T cells in patients with cerebellar degeneration. 21 Although limited information is available, one recently reported patient did not improve with tacrolimus, 71 and in another the side-effects worsened the patient's already limited quality of life (Dalmau J, unpublished).
The small number of patients with PND that can be seen in a single institution makes it difficult to identify new syndromes. Nevertheless, the most relevant discoveries in PND stem from clinical observations of patients with similar symptoms whose serum and CSF were subsequently investigated. With this approach, the immune responses identified show a high degree of syndrome specificity and are therefore clinically relevant. Studies based on largescale screening of sera or CSF with limited preselection clinical criteria rarely produce clinically relevant antibodies. New methods of antibody detection might be useful when standard results are negative. New approaches to detect antibodies to cell-surface antigens have revealed disorders that are indeed associated with antibodies. Similar studies should be pursued in patients with autoimmune opsoclonus and encephalitides, and expanded to other syndromes, because patients with these disorders are precisely those who are most likely to benefit from immunotherapy.
Search strategy and selection criteria
References for this Review were identified through searches of PubMed from 1966 to December 2007 with the terms "paraneoplastic", "cerebellar degeneration", "encephalitis, "limbic encephalitis", "opsoclonus", "cancer", "antibodies", "autoantigens". Only papers published in English in peer-reviewed journals were selected. Articles were also identified through searches of the authors' own files. 
